As the readouts from three late-stage Alzheimer’s disease drug candidates draw nearer, hopes are again rising that a breakthrough may finally be possible – but given the string of failures over the last 20 years, many are skeptical about the chances of success for the beta-amyloid targeting antibody therapies.
Eli Lilly believes its patient-stratification approach could give it the edge, but its readout looks set to be the last of the trio; Biogen and Eisai’s lecanemab is expected in September, Roche’s
